199 related articles for article (PubMed ID: 22292752)
1. MMPs in ovarian cancer as therapeutic targets.
Karam A; Dorigo O
Anticancer Agents Med Chem; 2012 Sep; 12(7):764-72. PubMed ID: 22292752
[TBL] [Abstract][Full Text] [Related]
2. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer.
Zhang Y; Chen Q
Braz J Med Biol Res; 2017 May; 50(6):e6104. PubMed ID: 28538838
[TBL] [Abstract][Full Text] [Related]
3. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.
Cai KQ; Yang WL; Capo-Chichi CD; Vanderveer L; Wu H; Godwin AK; Xu XX
Mol Carcinog; 2007 Feb; 46(2):130-43. PubMed ID: 17131304
[TBL] [Abstract][Full Text] [Related]
4. The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Escalona RM; Chan E; Kannourakis G; Findlay JK; Ahmed N
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393911
[TBL] [Abstract][Full Text] [Related]
5. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
Winer A; Adams S; Mignatti P
Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
Piperigkou Z; Manou D; Karamanou K; Theocharis AD
Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
[TBL] [Abstract][Full Text] [Related]
7. Seesaw of matrix metalloproteinases (MMPs).
Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment.
Stellas D; Patsavoudi E
Anticancer Agents Med Chem; 2012 Sep; 12(7):707-17. PubMed ID: 22292747
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
12. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitors.
Ramnath N; Creaven PJ
Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome.
Wang Y; Ye Y; Lin J; Meyer L; Wu X; Lu K; Liang D
Mol Carcinog; 2015 Jun; 54(6):430-9. PubMed ID: 25867973
[TBL] [Abstract][Full Text] [Related]
15. Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke RE; Libert C
Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy.
Gupta A; Kaur CD; Jangdey M; Saraf S
Ageing Res Rev; 2014 Jan; 13():65-74. PubMed ID: 24355347
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer: involvement of the matrix metalloproteinases.
Al-Alem L; Curry TE
Reproduction; 2015 Aug; 150(2):R55-64. PubMed ID: 25918438
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases in tumorigenesis: an evolving paradigm.
Hua H; Li M; Luo T; Yin Y; Jiang Y
Cell Mol Life Sci; 2011 Dec; 68(23):3853-68. PubMed ID: 21744247
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
